SOLTI Cancer Research Group
A Barcelona-based academic breast cancer group known for biomarker-driven trials that use PAM50 intrinsic subtypes to pick therapy.
Founded in 1995, SOLTI is a Spanish academic research group that designs translational breast cancer trials around molecular subtyping. PAMELA showed the HER2-enriched intrinsic subtype predicts response to dual HER2 blockade without chemotherapy, PATRICIA tested palbociclib with trastuzumab, and HARMONIA compares ribociclib with palbociclib in HER2-enriched luminal disease. SOLTI works closely with Vall d'Hebron and Hospital Clínic investigators, partners with the Breast International Group and industry, and runs window-of-opportunity and neoadjuvant designs with serial biopsies. Patient advocates sit on its scientific committee.
- PAM50-guided trials (PAMELA, HARMONIA)
- CDK4/6 inhibitor trials (PATRICIA)
- Window-of-opportunity and neoadjuvant designs
- BIG member group
Pages like this
not linked directly; found by shared links- InstitutionAustrian Breast & Colorectal Cancer Study Group
Shares Breast International Group (BIG), Palbociclib, CDK4/6 inhibitors, HER2-positive breast cancer.
- PairingCDK4/6 inhibitor + endocrine therapy
Shares Ribociclib, Palbociclib, CDK4/6 inhibitors, HR-positive / HER2-negative breast cancer.
- PersonDennis J. Slamon
Shares Ribociclib, Palbociclib, Trastuzumab, HER2-positive breast cancer.
- InstitutionInstitut Jules Bordet
Shares Breast International Group (BIG), RNA sequencing & expression profiling, Trastuzumab, HER2-positive breast cancer.
- InstitutionUNC Lineberger Comprehensive Cancer Center
Shares PAM50 / intrinsic subtypes, CDK4/6 inhibitors, Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer.
- PersonDebu Tripathy
Shares Ribociclib, HER2-positive breast cancer, Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer.
- InstitutionInstituto Alexander Fleming
Shares Palbociclib, Trastuzumab, HER2-positive breast cancer, HR-positive / HER2-negative breast cancer.
- InstitutionComprehensive Cancer Center Vienna – Medical University of Vienna / AKH
Shares Breast International Group (BIG), Palbociclib, CDK4/6 inhibitors, HR-positive / HER2-negative breast cancer.